Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
מצבים רפואיים
Juvenile Psoriatic Arthritis
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
University of Florida, Gainesville, Florida, United States
Contact: Principal Investigator (Christian Oliveros)Ann and Robert H Lurie Childs Hosp, Chicago, Illinois, United States
Contact: Principal Investigator (Pooja Patel)Levine Childrens Hospital, Charlotte, North Carolina, United States
Contact: Principal Investigator (Sheetal Vora)Cincinnati Childrens Hospital, Cincinnati, Ohio, United States
Contact: Study coordinator (Megan Quinlan-Waters) · Megan.Quinlan-Waters@cchmc.org · +1 513 636 7261Contact: Principal Investigator (Hermine Brunner)Univ Hosp Cleveland Medical Center, Cleveland, Ohio, United States
Contact: Principal Investigator (Ezequiel Borgia)Legacy Emanuel Research Hosp Portland, Portland, Oregon, United States
Contact: Principal Investigator (Daniel Joseph Kingsbury)Childrens Hosp Pittsburgh UPMC, Pittsburgh, Pennsylvania, United States
Contact: Principal Investigator (Margalit Rosenkranz)Texas Arthritis Center, El Paso, Texas, United States
Contact: Principal Investigator (Sanjay Chabra)